Integration of the cancer-related inflammatory response as a stratifying biomarker of survival in hepatocellular carcinoma treated with sorafenib.
Howell J, Pinato DJ, Ramaswami R, Arizumi T, Ferrari C, Gibbin A, Burlone ME, Guaschino G, Toniutto P, Black J, Sellers L, Kudo M, Pirisi M, Sharma R
"B in IT" - a community-based model for the management of hepatitis B patients in primary care clinics using a novel web-based clinical tool.
O'Leary DA, Cropp E, Isaac D, Desmond PV, Bell S, Nguyen T, Wong D, Howell J, Richmond J, O'Neill J, Thompson AJ
Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade.
Scott N, Doyle JS, Wilson DP, Wade A, Howell J, Pedrana A, Thompson A, Hellard ME
Review article: delivering precision oncology in intermediate-stage liver cancer.
Pinato DJ, Howell J, Ramaswami R, Sharma R
Hepatocellular Carcinoma After Sustained Virologic Response: Leave No One Behind.
Howell J, Thompson AJ
On-target sorafenib toxicity predicts improved survival in hepatocellular carcinoma: a multi-centre, prospective study.
Howell J, Pinato DJ, Ramaswami R, Bettinger D, Arizumi T, Ferrari C, Yen C, Gibbin A, Burlone ME, Guaschino G, Sellers L, Black J, Pirisi M, Kudo M, Thimme R, Park JW, Sharma R